<DOC>
	<DOCNO>NCT00858780</DOCNO>
	<brief_summary>This study involve Rheumatoid Arthritis patient regular clinical setting already etanercept treatment remission low disease activity ( LDA ) state , intend identify parameter serve guidance clinical setting . This study consider clinical radiographic course subject etanercept treatment tapered discontinue , analyze subject ' experience disease worsen predictive value clinical parameter , serum biomarkers image clinical radiographic course different treatment group . The effect re-treatment etanercept treatment failure also study .</brief_summary>
	<brief_title>Study Comparing The Effect On Disease Activity When Reducing Or Discontinuing Etanercept In Subjects With RA</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Inclusion criterion : Subject current DAS28 equal less 3.2 . Subject currently receive treatment etanercept , either 25 mg twice weekly 50 mg weekly , minimum 14 month baseline Subject currently receive oral , sc intramuscular methotrexate weekly , 7.5 mg/week 25 mg/week stable dose minimum 4 month baseline . Subject earlier attempt discontinue etanercept reason remission low disease activity state . Subject receive diseasemodifying antirheumatic drug , methotrexate , within one month baseline . Subject dose prednisone ( equivalent ) &gt; 7.5 mg/day receive intraarticular , intravenous , intramuscular , subcutaneous corticosteroid within one month baseline .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>